Post by Dr. Julita Panek

Senior Advisor Pharma R&D Transformation bei Siemens Advanta | Biotechnologie, Biowissenschaften

๐Ÿ’Š๐ŸŒŸLast weekโ€™s ๐๐ข๐จ๐ญ๐ž๐œ๐ก ๐’๐ฎ๐ฆ๐ฆ๐ข๐ญ ๐€๐ฎ๐ฌ๐ญ๐ซ๐ข๐š ๐ข๐ง ๐†๐ซ๐š๐ณ was truly memorable. Still energized. Still inspired. Still dancing (at least in my head). ๐Ÿ’ƒ This summit was a celebration of ๐œ๐จ๐ง๐ง๐ž๐œ๐ญ๐ข๐จ๐ง, ๐œ๐จ๐ฅ๐ฅ๐š๐›๐จ๐ซ๐š๐ญ๐ข๐จ๐ง, and ๐œ๐จ-๐œ๐ซ๐ž๐š๐ญ๐ข๐จ๐ง - and a clear signal for the future of biotech in Austria ๐Ÿ‡ฆ๐Ÿ‡น and Europe ๐Ÿ‡ช๐Ÿ‡บ. What stayed with me: โœจ Talks that inspired โ€“ beyond the slides ๐Ÿง  Panels that sparked real thought โ€“ and even more questions ๐Ÿค 1:1 meetings that turned into meaningful connections ๐ŸŒฟ Local charm โ€“ wine, nature & hospitality (thank you, ZETA) ๐Ÿ’ƒ Joy, laughter, dancing โ€“ because good energy drives good outcomes. What truly moved me: the authentic ๐ฅ๐ž๐š๐๐ž๐ซ๐ฌ๐ก๐ข๐ฉ of Lejla Pock, Peter Llewellyn-Davies and Klaus Weinberger showing how joyful professionalism can turn ๐œ๐จ๐ฆ๐ฉ๐ž๐ญ๐ข๐ญ๐ข๐จ๐ง ๐ข๐ง๐ญ๐จ ๐œ๐จ๐ฅ๐ฅ๐š๐›๐จ๐ซ๐š๐ญ๐ข๐จ๐ง. ๐Ÿ’ก My key takeaway: Biotech is a high-risk, high-impact industry โ€“ and real progress happens when we connect the dots across silos. ๐…๐ซ๐จ๐ฆ ๐ž๐š๐ซ๐ฅ๐ฒ ๐‘&๐ƒ ๐ญ๐จ ๐ฆ๐š๐ง๐ฎ๐Ÿ๐š๐œ๐ญ๐ฎ๐ซ๐ข๐ง๐ . ๐…๐ซ๐จ๐ฆ ๐๐š๐ญ๐š ๐ญ๐จ ๐ฆ๐ž๐๐ข๐œ๐ข๐ง๐ž.๐Ÿ’Šโžก๏ธโค๏ธ In my new role at Siemens Advanta, I reflected on how we can support this journey: ๐Ÿ“ End-to-end integration across the product & process lifecycle ๐Ÿ“ Data connectivity, contextualization & integrated IT architecture in early-stage research ๐Ÿ“ Simplifying systems access for CROs working across multiple tools ๐Ÿ“ Speeding up tech transfer โ€“ with strong data security & client confidentiality at CDMOs ๐Ÿ“ Co-creating smart workflows to streamline patient data entry and ease clinical studdies evaluation. When we have the courage to embrace change, new ideas, and new technologies โ€“ we can build a kind of ๐’๐ข๐ฅ๐ข๐œ๐จ๐ง ๐•๐š๐ฅ๐ฅ๐ž๐ฒ ๐Ÿ๐จ๐ซ ๐›๐ข๐จ๐ญ๐ž๐œ๐ก. ๐Ÿš€ ๐Ÿ™ Thank you,ย Harpreet Singh for your powerful reminder of ๐–๐‡๐˜ we do this: ๐…๐จ๐ซ ๐ญ๐ก๐ž ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ. Maybe even for our families.ย For more life. For better life. Itโ€™s an honor to be part of this mission. ๐Ÿ’ฌ What challenges are you facing in biotech right now? Letโ€™s talk and exchange maybe in ๐‹๐ข๐ฏ๐ข๐ง๐ ๐‹๐š๐› @ Siemens in Vienna and meet again in ๐ˆ๐ง๐ง๐ฌ๐›๐ซ๐ฎ๐œ๐ค ๐ข๐ง ๐Ž๐œ๐ญ๐จ๐›๐ž๐ซ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”! Sophie Zettl, Nicole Daniela Schlautmann, Dr. Christoph Klade, Jason Golan, Michaela Vancova, Christina Guttmann-Gruber, Hana Cernecka, Barbara Prietl, Jochen Bergmann, Matthias Mรผllner, Isabel Prammer, Patrik Frei, Georg Altenbacher Marc J. Brehme, PhD, MBA Georg Sachs #BiotechAustria #HumanTechnologyStyria #HealthHubTriol #Austria #Europe #Innovation #Collaboration #Ecosystem #Startup #CRO #CDMO #Investor #PatentAttorney

Post contentPost contentPost contentPost contentPost contentPost contentPost content